QQ客服 官方微博 反馈留言

	Stability of the recombinant anti-erbB2 scFv-Fc-interleukin-2 fusion protein and its inhibition of HER2-overexpressing tumor cells
	Du, Yu-Jia4; Lin, Ze-Min5; Zhao, Ying-Hua3; Feng, Xiu-Ping2; Wang, Chang-Qing2; Wang, Gang2; Wang, Chun-Di2; Shi, Wei2,3; Zuo, Jian-Ping1,5; Li, Fan4
刊名	INTERNATIONAL JOURNAL OF ONCOLOGY
	2013-02
卷号	42期号:2页码:507-516
关键词	anti-erbB2 scFv-Fc-interleukin-2 fusion protein antibody-cytokine fusion protein HER2 overexpression FVB/neu tumor immunotherapy
ISSN号	1019-6439
DOI	10.3892/ijo.2012.1747
文献子类	Article
英文摘要	The anti-erbB2 scFv-Fc-IL-2 fusion protein (HFI) is the basis for development of a novel targeted anticancer drug, in particular for the treatment of HER2-positive cancer patients. HFI was fused with the anti-erbB2 antibody and human IL-2 by genetic engineering technology and by antibody targeting characteristics of HFI. IL-2 was recruited to target cells to block HER2 signaling, inhibit or kill tumor cells, improve the immune capacity, reduce the dose of antibody and IL-2 synergy. In order to analyse HFI drug ability, HFI plasmid stability was verified by HFI expression of the trend of volume changes. Additionally, HFI could easily precipitate and had progressive characteristics and thus, the buffer system of the additive phosphate-citric acid buffer, arginine, Triton X-100 or Tween-80, the establishment of a microfiltration, ion exchange, affinity chromatography and gel filtration chromatography-based purification process were explored. HFI samples were obtained according to the requirements of purity, activity and homogeneity. In vivo, HFI significantly delayed HER2 overexpression of non-small cell lung cancer (Calu-3) in human non-small cell lung cancer xenografts in nude mice, and the inhibition rate was more than 60% (P<0.05) in the group treated with 1 mg/kg the HFI dose; HFI significantly inhibited HER2 expression of breast cancer (FVB/neu) trahsgenic mouse tumor growth in 1 mg/kg of the HFI dose group, and in the following treatment the 400 mm(3) tumors disappeared completely. Combined with other HFI test data analysis, HFI not only has good prospects, but also laid the foundation for the development of antibody-cytokine fusion protein-like drugs.
资助项目	'The Key New Drug Creation and Manufacturing' of the Eleventh Five-Year Plan[2009ZX09103-695]
WOS关键词	BREAST-CANCER CELLS ; REGULATORY T-CELLS ; TYROSINE KINASE INHIBITOR ; VERSUS-HOST-DISEASE ; IN-VITRO ; MONOCLONAL-ANTIBODIES ; SIGNAL-TRANSDUCTION ; GROWTH ; INTERLEUKIN-2 ; IMMUNOCYTOKINE
WOS研究方向	Oncology
语种	英语
出版者	SPANDIDOS PUBL LTD
WOS记录号	WOS:000314001000014
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/277754]
专题	药理学第一研究室 中科院受体结构与功能重点实验室 新药研究国家重点实验室
通讯作者	Li, Fan
作者单位	1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China 2.Gene Sci Pharmaceut Co Ltd, Pharmaceut R&D Ctr, Changchun 130012, Peoples R China; 3.Jilin Univ, Coll Life Sci, Minist Educt, Key Lab Mol Enzymol & Engn, Changchun, Peoples R China; 4.Jilin Univ, Norman Bethune Coll Med, Changchun 130021, Peoples R China; 5.Shanghai Univ Tradit Chinese Med, Lab Immunol & Virol, Shanghai 201203, Peoples R China;
推荐引用方式 GB/T 7714	Du, Yu-Jia,Lin, Ze-Min,Zhao, Ying-Hua,et al. Stability of the recombinant anti-erbB2 scFv-Fc-interleukin-2 fusion protein and its inhibition of HER2-overexpressing tumor cells[J]. INTERNATIONAL JOURNAL OF ONCOLOGY,2013,42(2):507-516.
APA	Du, Yu-Jia.,Lin, Ze-Min.,Zhao, Ying-Hua.,Feng, Xiu-Ping.,Wang, Chang-Qing.,...&Wang, Cheng-Zhong.(2013).Stability of the recombinant anti-erbB2 scFv-Fc-interleukin-2 fusion protein and its inhibition of HER2-overexpressing tumor cells.INTERNATIONAL JOURNAL OF ONCOLOGY,42(2),507-516.
MLA	Du, Yu-Jia,et al."Stability of the recombinant anti-erbB2 scFv-Fc-interleukin-2 fusion protein and its inhibition of HER2-overexpressing tumor cells".INTERNATIONAL JOURNAL OF ONCOLOGY 42.2(2013):507-516.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。